Premium
Caspofungin for invasive fungal infections: Combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation
Author(s) -
Pancham S.,
Hemmaway C.,
New H.,
Albert E.,
Dokal I.,
Roberts I. A. G.,
McCloy M.
Publication year - 2005
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/j.1399-3046.2005.00261.x
Subject(s) - caspofungin , medicine , amphotericin b , stem cell , transplantation , hematopoietic stem cell transplantation , antifungal , surgery , biology , dermatology , genetics
Invasive fungal infections often prove difficult to eradicate especially in the stem cell transplant setting. Amphotericin has been the mainstay of treatment for years but has significant toxicity. Newer antifungal agents, such as caspofungin, have shown promising results in adults, particularly when used in combination with amphotericin as both drugs differ in their mode of action. However, there are few data from children and no previous published information about the use of Caspofungin after paediatric stem cell transplantation. We report our experience in children with proven invasive fungal infections after stem cell transplantation. This combination was non‐toxic, and two of three patients survived their infections.